Gene Editing Advances: Precision BioSciences Unveils Promising HBV Trial Results and Strategic Insights In an era marked by dynamic scientific advancements, Precision BioSciences, Inc., a frontrunner in the realm of gene editing, has once again underscored its commitment to tackling diseases with profound unmet medical needs. Leveraging the innovative ARCUS platform, the Durham, N.C.-based company is making significant strides in the development of in vivo gene editing therapies. Recently, at the 6th International Coalition to Eliminate HBV Cure Symposium in Berlin, Germany, Precision BioSciences presented groundbreaking data from its Phase 1 ELIMINATE-B trial, aimed at chronic Hepatitis B (HBV), while also ...
Precision BioSciences to Engage in Investor Conferences Amidst Market Challenges Precision BioSciences, a prominent player in the field of genome editing and therapeutic development, is set to participate in a series of investor conferences throughout November. This engagement is part of the company s ongoing effort to communicate its corporate strategies, innovation pipeline, and financial outlook with current and prospective investors. This initiative comes at a crucial time as the company s market performance faces challenges.In recent weeks, Precision BioSciences stock has not kept pace with the overall market, showing a weaker performance compared to broader market indices. Specifically, Precision BioS...
Precision BioSciences Clears Milestone with FDA Approval for TG Therapeutics Azer-Cel in Multiple Sclerosis Investigation By for CSIMarket.com Durham, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, has announced a significant milestone achieved in collaboration with its partner TG Therapeutics. The U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application for Azercabtagene Zapreleucel (Azer-Cel), a gene therapy candidate targeting multiple sclerosis (MS).Precision BioSciences is renowned for its innovative ARCUS platform, a proprietary gene editing technology designed for sophisticated genomic alterations includ...
The realm of gene editing is witnessing transformative advancements, and at the forefront of this evolution is Precision BioSciences, Inc. (Nasdaq: DTIL). The recent announcement regarding the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application by partner TG Therapeutics for Azer-Cel marks a significant milestone not only for the companies involved but also for the treatment landscape of multiple sclerosis (MS). Key Facts 1. Company Overview : Precision BioSciences, based in Durham, North Carolina, is recognized for its innovative ARCUS gene editing platform. This proprietary technology enables precise gene edits, including gene elimination, insertion, and exci...
Precision BioSciences: Pioneering Advances in Gene Editing and Multiple Sclerosis TreatmentIn recent announcements, Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering gene editing company, has made significant strides in advancing its innovative therapies and expanding its market presence. With a focus on novel gene editing techniques through its proprietary ARCUS platform, Precision BioSciences is well-positioned to reshape the landscape of genetic medicine. This article delves into the latest developments surrounding the company, particularly its collaborations, product advancements, and its recent inclusion in major stock indices. Investigational New Drug Clearance for Azer-CelOne of the landmark a...
Precision BioSciences Bolsters Hepatitis Scientific Advisory Board with Mark Sulkowski and Jordan Feld as PBGENE-HBV Program AdvancesDURHAM, N.C. - Precision BioSciences, a leading gene editing company specializing in advanced in vivo gene editing therapies, has recently announced the appointment of two renowned clinical investigators, Mark Sulkowski, M.D., and Jordan Feld, M.D., M.P.H., to its Hepatitis Scientific Advisory Board (SAB). The addition of these world-class experts comes as the company s PBGENE-HBV program approaches clinical readiness, marking a significant milestone in Precision BioSciences aim to combat hepatitis.Precision BioSciences is known for its cutting-edge ARCUS platform, a proprieta...
Sources:
Precision Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Precision Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Precision Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
